tbuckley/cabot-search huggingface dataset:
The role of interleukin-17 in tumor development and progression
Authors: Junjie Zhao, Xing Chen, Tomasz Herjan, Xiaoxia Li
Journal: The Journal of Experimental Medicine (2019)

IL-17, a potent proinflammatory cytokine, has been shown to intimately contribute to the formation, growth, and metastasis of a wide range of malignancies. Recent studies implicate IL-17 as a link among inflammation, wound healing, and cancer. While IL-17–mediated production of inflammatory mediators mobilizes immune-suppressive and angiogenic myeloid cells, emerging studies reveal that IL-17 can directly act on tissue stem cells to promote tissue repair and tumorigenesis. Here, we review the pleotropic impacts of IL-17 on cancer biology, focusing how IL-17–mediated inflammatory response and mitogenic signaling are exploited to equip its cancer-promoting function and discussing the implications in therapies.
PD1.05 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced Non-small-cell Lung Cancer (CLICAP-ABs)
Authors: F. Barrón, A.F. Cardona, A. Ruiz-Patiño, L. Zatarain Barron, L. Corrales-Rodriguez, C. Martín, C. Sotelo, J. Rodríguez, J. Ávila, D. Mayorga, P. Archila, L. Mas, H. Freitas, V.C. Cordeiro De Lima, J. Otero, H. Carranza, C. Vargas, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
Fostering Resilience Among Youths Exposed to Adverse Childhood Experiences
Authors: Kira E. Riehm, Kenneth A. Feder
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
PATH-63. TRANSCRIPTIONAL SIGNATURES IN HISTOLOGIC STRUCTURES WITHIN GLIOBLASTOMA TUMORS MAY PREDICT PERSONALIZED TREATMENT SENSITIVITY AND SURVIVAL
Authors: Cymon Kersch, Cheryl Claunch, Prakash Ambady, Elmar Bucher, Daniel Schwartz, Ramon Barajas, Jeffrey Iliff, Laura Heiser, Leslie Muldoon, Edward Neuwelt
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE Personalized treatment strategies in Glioblastoma multiforme (GBM) has been hampered by intra-tumoral heterogeneity. The goals of this study were to (1) determine the impact of intra-tumoral heterogeneity on established predictive and prognostic transcriptional signatures in human GBM, and (2) develop methods to mitigate the impact of tissue heterogeneity on transcriptomic-based patient stratification. METHODS We analyzed transcriptional profiles of GBM histological structures from the open-source Ivy Glioblastoma Atlas Project. To generate these data, infiltrative tumor, leading edge, cellular tumor [CT], perinecrotic zones, pseudopalisading cells, hyperplastic blood vessels and microvascular proliferation were microdissected from 34 newly diagnosed GBM and underwent RNA sequencing. Data from The Cancer Genome Atlas were used for validation. Principle component analysis, network analysis and gene set enrichment analysis were used to probe gene expression patterns. RESULTS Distinct biological networks were enriched in each tumor histological structure. Classification of patients into GBM molecular subtypes varied based on the structure assessed, with many patients classified as every subtype depending on the structure analyzed. Using only CT to classify subtypes, we identified biologically unique patterns suggesting that proneural and mesenchymal tumors may be more sensitive to chemoradiotherapy and immunotherapy, respectively. Survival outcome predicted by an established multigene panel was confounded by histologic structure. Utilizing CT transcriptomics we developed a novel survival prediction gene signature that identified the highest-risk GBM patients in both CT and bulk tissue gene expression profiles. CONCLUSIONS Histologic structures contribute to intra-tumoral heterogeneity in GBM. Using mixed-structure biopsy samples could incorrectly subtype tumors and produce invalid patient stratification. Limiting transcriptomic analysis to the CT allowed us to develop a new survival prediction gene signature that appears accurate even in mixed tissue samples. The biological patterns uncovered in the subtypes and risk-stratified groups have important implications for guiding the development of precision medicine in GBM.
RDNA-10. TTFIELDS TREATMENT PLANNING FOR TARGETING MULTIPLE LESIONS SPREAD THROUGHOUT THE BRAIN
Authors: Ariel Naveh, Ofir Yesharim, Ze’ev Bomzon
Journal: Neuro-Oncology (2019)

Abstract Tumor Treating Fields (TTFields) are approved for the treatment of Glioblastoma Multiforme (GBM) in supratentorium. When treating GBM in the suprtaentorial brain, TTFields are delivered using 2 pairs of transducer arrays positioned in close proximity to the tumor. This results in an increased TTFields dose in the affected tumor region, whilst reducing the dose in other regions, particularly the infratentorium. Brain metastases, occur in 10 to 30 percent of adults with cancer, and can occur throughout the brain, including in infratentorial regions. Therefore, when using TTFields to treat brain metastases, it is desirable to deliver TTFields at therapeutic intensities to the entire brain or to the infratentorium depending on the location of the lesions. We performed computational studies to identify array layouts for delivering TTFields at therapeutic intensities to the infratentorium and to the entire brain. The computer simulations utilized a realistic computerized head model of a 40+ years old human male prepared in-house. TTFields could be delivered effectively to the infratentorium using a layout in which a pair of arrays was placed on the lateral aspects of the neck below the ears, and the second pair on the upper head and lower neck yielded field intensities above 1 V/cm in the infratentorial brain. Other layouts in which one pair of arrays was placed on the right temple and left scapula, and the second pair placed on the left temple and right scapula yielded a uniform intensity distribution within the entire brain. This layout could be useful for treating multiple lesion spread in both the infratentorial and supratentorial regions. This study suggests that careful treatment planning could be used to optimize TTFields treatment targeting multiple lesions spread throughout the brain.
Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss
Authors: Ruth Sapir-Pichhadze, Xun Zhang, Abdelhakim Ferradji, Abeer Madbouly, Kathryn J. Tinckam, Howard M. Gebel, Daniel Blum, Marilyn Marrari, S. Joseph Kim, Stephanie Fingerson, Pradeep Bashyal, Héloïse Cardinal, Bethany J. Foster
Journal: Kidney International (2019)
An IFN-γ and TNF-α dual release fluorospot assay for diagnosing active tuberculosis
Authors: J.Y. Kim, Y.A. Kang, J.H. Park, H.H. Cha, N.Y. Jeon, S.W. Lee, S.O. Lee, S.-H. Choi, Y.S. Kim, J.H. Woo, S.-H. Kim
Journal: Clinical Microbiology and Infection (2019)
A Consensus Framework for the Humanitarian Surgical Response to Armed Conflict in 21st Century Warfare
Authors: Sherry M. Wren, Hannah B. Wild, Jennifer Gurney, Mohana Amirtharajah, Zachary W. Brown, Eileen M. Bulger, Frederick M. Burkle, Eric A. Elster, Joseph D. Forrester, Kent Garber, Richard A. Gosselin, Reinou S. Groen, Gary Hsin, Manjul Joshipura, Adam L. Kushner, Ian Norton, Inga Osmers, Heather Pagano, Tarek Razek, Jesús-Manuel Sáenz-Terrazas, Lilli Schussler, Barclay T. Stewart, Abd Al-Rahman Traboulsi, Miguel Trelles, John Troke, Christopher A. VanFosson, Paul H. Wise
Journal: JAMA Surgery (2019)

Armed conflict in the 21st century poses new challenges to a humanitarian surgical response, including changing security requirements, access to patients, and communities in need, limited deployable surgical assets, resource constraints, and the requirement to address both traumatic injuries as well as emergency surgical needs of the population. At the same time, recent improvements in trauma care and systems have reduced injury-related mortality. This combination of new challenges and medical capabilities warrants reconsideration of long-standing humanitarian surgery protocols.To describe a consensus framework for surgical care designed to respond to this emerging need.An international group of 35 representatives from humanitarian agencies, US military, and academic trauma programs was invited to the Stanford Humanitarian Surgical Response in Conflict Working Group to engage in a structured process to review extant trauma protocols and make recommendations for revision.The working group's method adapted core elements of a modified Delphi process combined with consensus development conference from August 3 to August 5, 2018.Lessons from civilian and military trauma systems as well as recent battlefield experiences in humanitarian settings were integrated into a tiered continuum of response from point of injury through rehabilitation. The framework addresses the security and medical requirements as well as ethical and legal principles that guide humanitarian action. The consensus framework includes trained, lay first responders; far-forward resuscitation/stabilization centers; rapid damage control surgical access; and definitive care facilities. The system also includes nontrauma surgical care, injury prevention, quality improvement, data collection, and predeployment training requirements.Evidence suggests that modern trauma systems save lives. However, the requirements of providing this standard of care in insecure conflict settings places new burdens on humanitarian systems that must provide both emergency and trauma surgical care. This consensus framework integrates advances in trauma care and surgical systems in response to a changing security environment. It is possible to reduce disparities and improve the standard of care in these settings.
A Systematic Review on Efficacy and Safety of Lenalidomide Based Regimens for Treatment of Newly Diagnosed Amyloidosis
Authors: Muhaddis Ejaz Ahmad, Muhammad Abdullah Yousaf, Mustafa Nadeem Malik, Abdul Rafae, Tariq Iqtidar Sadiq Syed, Syed Maaz Abdullah, Zunairah Shah, Fazeel Qamar, Ahmed Ibrahim, Faiz Anwer
Journal: Blood (2019)
Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?
Authors: Gonzalo Blanco, Anna Puiggros, Barbara Sherry, Lara Nonell, Xavier Calvo, Eulalia Puigdecanet, Pui Yan Chiu, Yasmine Kieso, Gerardo Ferrer, Magdalena Arnal, María Rodríguez-Rivera, Eva Gimeno, Eugenia Abella, Kanti R Rai, Pau Abrisqueta, Francesc Bosch, Ana Ferrer, Nicholas Chiorazzi, Blanca Espinet
Journal: Blood (2019)
Pulmonary Alveolar Microlithiasis
Authors: W. B. Thomson
Journal: Thorax (1959)

We have treated PIK23 cells ( P815 cells genetically modified to express ovalbumin in an inducible manner) with irreversible proteasome inhibitors AdaAhx3L3VS and lactacystin and analyzed (a) the ability of inhibitors to block proteasome activity by in-gel peptidase assay, and (b) the generation of new cell surface Kb-SIINFEKL complexes as measured by B3Z activation. Our results show that complete inhibition of proteasome activity results in only a modest inhibition in generation of new Kb-SIINFEKL complexes. Only a combined inhibition of proteasomes and other cytosolic proteases leads to a complete inhibition of generation of such complexes. These results point to existence of redundant pathways for generation of SIINFEKL.
Heart Rate Dynamics at the Onset of Ventricular Tachyarrhythmias as Retrieved From Implantable Cardioverter-Defibrillators in Patients With Coronary Artery Disease
Authors: EtiennePruvot, GillesThonet, Jean-MarcVesin, Guyvan-Melle, KarlheinzSeidl, HerwigSchmidinger, JohannesBrachmann, WernerJung, EllenHoffmann, RenéTavernier, MichaelBlock, AndreaPodczeck, MartinFromer
Journal: Circulation (2000)

Background—The recent availability of implantable cardioverter-defibrillators (ICDs) that record 1024 R-R intervals preceding a ventricular tachyarrhythmia (VTA) provides a unique opportunity to analyze heart rate variability (HRV) before the onset of VTA. Methods and Results—Fifty-eight post–myocardial infarction patients with an implanted ICD for recurrent VTA provided 2 sets of 98 heart rate recordings in sinus rhythm: (1) before a VTA and (2) during control conditions. Three subgroups were considered according to the antiarrhythmic (AA) drug regimen. A state of sympathoexcitation was suggested by the significant reduction in HRV before VTA onset compared with control conditions. β-Blockers and dl-sotalol enhanced HRV in control recordings; nevertheless, HRV declined before VTA independent of AA drugs. A gradual increase in heart rate and decrease in sinus arrhythmia at VTA onset were specific findings of patients who received dl-sotalol. Conclusions—The peculiar heart rate dynamics observed before VTA...
The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative
Authors: Allison Barraclough, Edward Yoo, Chan Y. Cheah, Dipti Talaulikar, Bianca Nguyen, Michelle Turner, Fatima Tahir, Jing Huang, Colm Keane, Mitchel Lincoln, Tara Cochrane, Anna M. Johnston, Michael Dickinson, Stephen Opat, Zoe McQuilten, Erica M. Wood, Gayathri St George, Cameron Wellard, Eliza A Hawkes
Journal: Blood (2019)
SCIDOT-31. DELAYED CONTRAST MRI FOR HIGH SENSITIVITY DEPICTION OF SUBTLE BBB DISRUPTION IN BRAIN PATHOLOGIES AND AS MEANS FOR MONITORING/DEVELOPING BBB DISRUPTION TECHNOLOGIES
Authors: Shirely Sharabi, David Last, Dianne Daniels, Itzik Cooper, Yael Bresler, Ester Shohami, Sigal Liraz-zaltsman, Yael Mardor
Journal: Neuro-Oncology (2019)

Abstract Understanding the effects of BBB disrupting technologies on the neurovascular unit is important for safety and for optimal timing of therapeutic agents administration. We studied the effects of two novel BBB disrupting methods employing pulsed electrical fields (PEFs) on wash-in/wash-out rates and on vascular dilatation/constriction in mice and rats. The first method uses high, minimal-invasive PEFs inducing electroporation in endothelial cells. The second employs low, non-invasive PEFs inducing tight-junction function alterations. Both were found to induce transient BBB disruption. Contrast-enhanced T1-weighted MRI (T1-Gd) and treatment response assessment maps (TRAMs) based on delayed-contrast MRI, were applied to depict BBB permeability, wash-in/wash-out rates and vascular dilatation/constriction. T1-Gd, acquired following high PEFs application, showed immediate enhancement in the treatment area, lasting for ~1 hour. However, TRAMs, obtained at different times post treatment (immediately-24 hours) indicated vasodilatation with fast wash-in/wash-out immediately post treatment (preventing efficient tissue accumulation of peripherally administered drugs) and delayed (~1 hour post PEFs) vasoconstriction, lasting several hours. This was followed by large volumes of subtle BBB disruption, visible mainly on TRAMs. These volumes exceeded the original volumes observed immediately post treatment, suggesting this may be the optimal time for drug administration. Low PEFs however, induced subtle BBB disruption, depicted only in the TRAMs, with slow contrast accumulation, reaching a plateau at ~40 min post treatment. The TRAMs showed significantly increased sensitivity to BBB disruption compared to T1-Gd also in mice post traumatic brain injury. Lesion volumes depicted in the TRAMs were x2.5 larger than the enhancing volumes on T1-Gd (p&lt;0.02). The results significantly correlated with histological assessment of blood vessels coverage by astrocytes end-feet (r2=0.77, p&lt;0.05), an histological indicator for BBB integrity. These results demonstrate the TRAMs advantages in depicting BBB disruption with high sensitivity/resolution, thus providing additional information regarding the neurovascular unit function.
Mutation of Murine Rpl5 reveals a New Model for Diamond Blackfan Anemia Characterized By Defective Erythropoiesis
Authors: Philippe Lemay, Morgan A Jones, Fatma Mohamed, Marie-Claude Guyot, Alexander Ludlow, Qing Li, James Douglas Engel, Renny Franceschi, Thomas L. Rothstein, Vesa Kaartinen, Zoha Kibar, Sharon A Singh
Journal: Blood (2019)
The Infection-Driven Production/Secretion of Inflammatory Cytokines By Circulating Monocytes of Myelofibrosis Is Defective and Is Reactivated after In VivoJAK1/2 Inhibition
Authors: Martina Barone, Francesca Ricci, Marco Romano, Dorian Forte, Giuseppe Auteri, Francesco Fabbri, Emanuela Ottaviani, Pierluigi Tazzari, Nicola Vianelli, Giovanni Martinelli, Michele Cavo, Francesca Palandri, Lucia Catani
Journal: Blood (2019)
Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial
Authors: Gregory L Krauss, Pavel Klein, Christian Brandt, Sang Kun Lee, Ivan Milanov, Maja Milovanovic, Bernhard J Steinhoff, Marc Kamin
Journal: The Lancet Neurology (2019)
Erratum to: DDIS-27. TARGETING ATP DOCKING AND P35/P25 BINDING OF CDK5 IN GLIOMA STEM CELLS USING SYNTHETIC INHIBITORS
Authors: Subhas Mukherjee, Gary Schiltz, Matt Clutter, Rama Mishra, Cheryl Olson, Bilge Dundar, Nitya Sharma, Steven Markwell, Daniel Brat
Journal: Neuro-Oncology (2021)
Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications
Authors: Jun Wei, Peiwen Chen, Pravesh Gupta, Martina Ott, Daniel Zamler, Cynthia Kassab, Krishna P Bhat, Michael A Curran, John F de Groot, Amy B Heimberger
Journal: Neuro-Oncology (2019)

CNS immune defenses are marshaled and dominated by brain resident macrophages and microglia, which are the innate immune sentinels and frontline host immune barriers against various pathogenic insults. These myeloid lineage cells are the predominant immune population in gliomas and can constitute up to 30-50% of the total cellular composition. Parenchymal microglial cells and recruited monocyte-derived macrophages from the periphery exhibit disease-specific phenotypic characteristics with spatial and temporal distinctions and are heterogeneous subpopulations based on their molecular signatures. A preponderance of myeloid over lymphoid lineage cells during CNS inflammation, including gliomas, is a contrasting feature of brain immunity relative to peripheral immunity. Herein we discuss glioma-associated macrophage and microglia immune biology in the context of their identity, molecular drivers of recruitment, nomenclature and functional paradoxes, therapeutic reprogramming and polarization strategies, relevant challenges, and our perspectives on therapeutic modulation.
Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome
Authors: Ali Sakhdari, Caleb Class, Guillermo Montalban-Bravo, Koji Sasaki, Carlos E. Bueso-Ramos, Keyur P. Patel, Joseph D. Khoury, Hagop M. Kantarjian, Guillermo Garcia-Manero, L. Jeffrey Medeiros, Rashmi Kanagal-Shamanna
Journal: Blood (2019)
Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
Authors: Ajai Chari, Sagar Lonial, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Joan Bladé, Lotfi Benboubker, Albert Oriol, Paula Rodriguez Otero, Luis Pineiro, Andrzej Jakubowiak, Yunsi Olyslager, Jianping Wang, Ivo Nnane, Jon Ukropec, Martin Shreeve, Ming Qi, Philippe Moreau
Journal: Blood (2019)
Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
Authors: Stefan K. Barta, Nathan H. Fowler, Jasmine Zain, Jia Ruan, Sonali M. Smith, Stephen J. Schuster, Sunita D Nasta, Jakub Svoboda, James N Gerson, Daniel J. Landsburg, Elise A. Chong, Henry C. Fung, Kerry S Campbell, Nadia Khan, Richard I. Fisher, Carlyn Rose Tan
Journal: Blood (2019)
Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study
Authors: Massimiliano Bonifacio, Mario Tiribelli, Gianni Binotto, Maria Cristina Miggiano, Marco Basso, Elisabetta Calistri, Luigi Scaffidi, Rossella Stella, Luca Frison, Roberto Sartori, Marco Ruggeri, Gianpietro Semenzato, Renato Fanin, Mauro Krampera
Journal: Blood (2019)
ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Garni Barkhoudarian, Nicholas Blondin, Sajeel Chowdhary, Ekokobe Fonkem, Brian Vaillant, Santosh Kesari
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The EMulate Therapeutics Voyager system is an investigational non-sterile, non-invasive, non-thermal, non-ionizing, portable, home-use medical device that uses a specific, localized ultra-low radio frequency energy (ulRFE®) cognate for the treatment of brain cancer. METHODS This open-label, multi-center study (NAT-109) enrolled adults newly diagnosed with GBM. Following surgical debulking, patients were enrolled and treated concurrently with temozolomide, radiotherapy, and Voyager. The objective of the study is to assess if the Voyager is a safe and feasible treatment for newly diagnosed GBM when combined with standard of care. The primary outcome measure is safety, assessed by the incidence and evaluation of any adverse events (AEs) associated with the Voyager. The secondary outcome measure is clinical utility, assessed by progression-free survival and overall survival. RESULTS Enrollment is closed, and treatment and long-term follow-up is ongoing. A total of 37 patients were enrolled and treated. 27 patients reported 282 AEs, none of which required withdrawal from the study. One AE was reported as probably related to the device - i.e., mild dysesthesia, which resolved without interruption or cessation of treatment with the device. 15 patients reported 28 SAEs, and none were reported as related to the device. 56% of patients were progression-free at 6 months, and 43% were progression-free at 12 months. 89% of patients were still alive after 6 months, 71% were still alive after 12 months. CONCLUSIONS The Voyager system appears to be safe and feasible for the treatment of newly diagnosed GBM. Given that therapy is delivered non-invasively and no device-related serious adverse events were reported, further prospective study of the investigational device is planned.